PURPOSE: To demonstrate the feasibility of using DNP hyperpolarized [1-(13)C]-pyruvate to measure early response to temozolomide (TMZ) therapy using an orthotopic human glioblastoma xenograft model. MATERIALS AND METHODS: Twenty athymic rats with intracranial implantation of human glioblastoma cells were divided into two groups: one group received an oral administration of 100 mg/kg TMZ (n = 10) and the control group received vehicle only (n = 10). (13)C 3D magnetic resonance spectroscopic imaging (MRSI) data were acquired following injection of 2.5 mL (100 mM) hyperpolarized [1-(13)C]-pyruvate using a 3T scanner prior to treatment (day D0), at D1 (days from treatment) or D2. RESULTS: Tumor metabolism as assessed by the ratio of lactate to pyruvate (Lac/Pyr) was significantly altered at D1 for the TMZ-treated group but tumor volume did not show a reduction until D5 to D7. The percent change in Lac/Pyr from baseline was statistically different between the two groups at D1 and D2 (P < 0.008), while percent tumor volume was not (P > 0.2). CONCLUSION: The results from this study suggest that metabolic imaging with hyperpolarized [1-(13)C]-pyruvate may provide a unique tool that clinical neuro-oncologists can use in the future to monitor tumor response to therapy for patients with brain tumors.
PURPOSE: To demonstrate the feasibility of using DNP hyperpolarized [1-(13)C]-pyruvate to measure early response to temozolomide (TMZ) therapy using an orthotopic humanglioblastoma xenograft model. MATERIALS AND METHODS: Twenty athymic rats with intracranial implantation of humanglioblastoma cells were divided into two groups: one group received an oral administration of 100 mg/kg TMZ (n = 10) and the control group received vehicle only (n = 10). (13)C 3D magnetic resonance spectroscopic imaging (MRSI) data were acquired following injection of 2.5 mL (100 mM) hyperpolarized [1-(13)C]-pyruvate using a 3T scanner prior to treatment (day D0), at D1 (days from treatment) or D2. RESULTS:Tumor metabolism as assessed by the ratio of lactate to pyruvate (Lac/Pyr) was significantly altered at D1 for the TMZ-treated group but tumor volume did not show a reduction until D5 to D7. The percent change in Lac/Pyr from baseline was statistically different between the two groups at D1 and D2 (P < 0.008), while percent tumor volume was not (P > 0.2). CONCLUSION: The results from this study suggest that metabolic imaging with hyperpolarized [1-(13)C]-pyruvate may provide a unique tool that clinical neuro-oncologists can use in the future to monitor tumor response to therapy for patients with brain tumors.
Authors: Casilda Balmaceda; Dana Critchell; Xiangling Mao; Kenneth Cheung; Susan Pannullo; Robert L DeLaPaz; Dikoma C Shungu Journal: J Neurooncol Date: 2006-01 Impact factor: 4.130
Authors: Jerzy Walecki; Eugeniusz Tarasów; Bozena Kubas; Zbigniew Czemicki; Janusz Lewko; Jan Podgórski; Maria Sokól; Pawel Grieb Journal: Acad Radiol Date: 2003-02 Impact factor: 3.173
Authors: N Shastry Akella; Donald B Twieg; Tom Mikkelsen; Fred H Hochberg; Stuart Grossman; Gretchen A Cloud; L Burt Nabors Journal: J Magn Reson Imaging Date: 2004-12 Impact factor: 4.813
Authors: Sam E Day; Mikko I Kettunen; Ferdia A Gallagher; De-En Hu; Mathilde Lerche; Jan Wolber; Klaes Golman; Jan Henrik Ardenkjaer-Larsen; Kevin M Brindle Journal: Nat Med Date: 2007-10-28 Impact factor: 53.440
Authors: Charles H Cunningham; Albert P Chen; Mark J Albers; John Kurhanewicz; Ralph E Hurd; Yi-Fen Yen; John M Pauly; Sarah J Nelson; Daniel B Vigneron Journal: J Magn Reson Date: 2007-06-02 Impact factor: 2.229
Authors: Myriam M Chaumeil; Peder E Z Larson; Hikari A I Yoshihara; Olivia M Danforth; Daniel B Vigneron; Sarah J Nelson; Russell O Pieper; Joanna J Phillips; Sabrina M Ronen Journal: Nat Commun Date: 2013 Impact factor: 14.919
Authors: Oleg G Salnikov; Nikita V Chukanov; Roman V Shchepin; Isaac V Manzanera Esteve; Kirill V Kovtunov; Igor V Koptyug; Eduard Y Chekmenev Journal: J Phys Chem C Nanomater Interfaces Date: 2019-04-19 Impact factor: 4.126
Authors: Marina Radoul; Chloé Najac; Pavithra Viswanath; Joydeep Mukherjee; Mark Kelly; Anne Marie Gillespie; Myriam M Chaumeil; Pia Eriksson; Romelyn Delos Santos; Russell O Pieper; Sabrina M Ronen Journal: NMR Biomed Date: 2018-12-18 Impact factor: 4.044
Authors: Jae Mo Park; Lawrence D Recht; Sonal Josan; Milton Merchant; Taichang Jang; Yi-Fen Yen; Ralph E Hurd; Daniel M Spielman; Dirk Mayer Journal: Neuro Oncol Date: 2013-01-17 Impact factor: 12.300
Authors: Elavarasan Subramani; Marina Radoul; Chloe Najac; Georgios Batsios; Abigail R Molloy; Donghyun Hong; Anne Marie Gillespie; Romelyn Delos Santos; Pavithra Viswanath; Joseph F Costello; Russell O Pieper; Sabrina M Ronen Journal: Cancer Res Date: 2020-09-21 Impact factor: 12.701
Authors: Richard G Abramson; Lori R Arlinghaus; Adrienne N Dula; C Chad Quarles; Ashley M Stokes; Jared A Weis; Jennifer G Whisenant; Eduard Y Chekmenev; Igor Zhukov; Jason M Williams; Thomas E Yankeelov Journal: Magn Reson Imaging Clin N Am Date: 2016-02 Impact factor: 2.266
Authors: Zhen J Wang; Michael A Ohliger; Peder E Z Larson; Jeremy W Gordon; Robert A Bok; James Slater; Javier E Villanueva-Meyer; Christopher P Hess; John Kurhanewicz; Daniel B Vigneron Journal: Radiology Date: 2019-03-05 Impact factor: 11.105